Latest News on MCK

Financial News Based On Company


Advertisement
Advertisement

Jim Cramer Says Cardinal Health Is "the Stock That Is Made for This Moment"

https://247wallst.com/investing/2026/11/20/jim-cramer-says-cardinal-health-is-the-stock-that-is-made-for-this-moment/
Jim Cramer highlighted Cardinal Health (CAH) as "the stock that is made for this moment," noting its strong performance with shares climbing 34% year-to-date. The company recently beat earnings and revenue estimates, raised guidance, and renewed a critical contract with CVS through 2032. While the stock's valuation at 22x forward earnings suggests much of the rally is priced in, its defensive nature and consistent profitability make it a durable compounder for long-term investors.

Federal judge sides with drug distributors in Cabell County opioid lawsuit

https://wchstv.com/news/local/federal-judge-sides-with-drug-distributors-in-cabell-county-opioid-lawsuit
A federal judge has once again ruled in favor of major drug distributors AmerisourceBergen, Cardinal Health, and McKessen Corporation, dismissing a lawsuit by Cabell County and Huntington that alleged the companies contributed to the opioid crisis. U.S. District Judge David Faber stated that medical professionals and pharmacies, not the distributors, were largely responsible for the oversupply of prescription opioids. This ruling reaffirms a previous 2022 decision that found the sale and distribution of prescription drugs were not covered under West Virginia’s common law of public nuisance.

McKesson falls 2.05% in Thursday's session

https://www.globalbankingandfinance.com/mckesson-mck-falls-2026-11-19/
McKesson's shares experienced a decline of 2.05% in Thursday's trading session, closing at $1,062.16. The company's market capitalization stands at $124.36 billion within the United States health care sector. This movement is reported as McKesson's stock traded significantly away from its previous close, meeting the criteria for this market report.

Two Deals and a Higher Target: UBS’s Call on McKesson (MCK)

https://ca.finance.yahoo.com/news/two-deals-higher-target-ubs-223331229.html
UBS analyst Kevin Caliendo raised his price target on McKesson (MCK) to $1,250 from $1,200, maintaining a Buy rating after the company reported strong Q2 fiscal 2027 results. McKesson's revenue increased by 8% to $111.0 billion, and adjusted earnings per share rose 18% to $11.68, prompting the company to raise its full-year EPS guidance. Additionally, McKesson expanded its operations through a minority stake in Option Care Health and the acquisition of Precision Medicine Group, strengthening its oncology and biopharma services.

HCA Healthcare and Learning Undefeated Bring Mobile STEM Lab to Herndon High School

https://wjla.com/good-morning-washington/hca-healthcare-and-learning-undefeated-bring-mobile-stem-lab-to-herndon-high-school-hca-healthcarelearning-undefeatedmobile-stem-labherndon-high-schoolstem-educationstem-learningstem-programs-for-studentsstem-outreachstem-opportunitiesscience-te
HCA Healthcare and Learning Undefeated partnered to bring a 1,000-square-foot Mobile Exploration Lab to Herndon High School, offering students hands-on experience in healthcare careers. Students engaged in an interactive activity mirroring real-world patient care, focusing on diabetes and glucose monitoring. The initiative aims to inspire the next generation of healthcare talent in Northern Virginia and showcase diverse career opportunities beyond traditional doctor and nurse roles.
Advertisement

Trading Systems Reacting to (MCK) Volatility

https://news.stocktradersdaily.com/news_release/141/Trading_Systems_Reacting_to_MCK_Volatility_111926062801_1795087681.html
This article from Stock Traders Daily analyzes McKesson Corporation (NYSE: MCK) with AI-generated trading strategies. It presents neutral near-term readings but strong mid-term sentiment, with no clear price positioning signal identified. The report provides detailed trading plans, including entry, target, and stop loss levels for position trading, momentum breakout, and risk hedging strategies.

McKesson Corporation (MCK) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_3176_AnalystReport_1794855055000
Argus analyst David H. Toung has raised the target price for McKesson Corporation (MCK) stock, maintaining a "Buy" rating. The report, published on November 16, 2026, highlights McKesson's operations across North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical segments.

Gartner ranks healthcare supply chains, led by AdventHealth

https://www.dcvelocity.com/finance-strategy/strategy/gartner-ranks-healthcare-supply-chains-led-by-adventhealth
Gartner's "Healthcare Supply Chain Top 25 for 2026" report named AdventHealth as the top performer for the third consecutive year, followed by Stanford Medicine, Bon Secours Mercy Health, Corewell Health, and Northwestern Medicine. The leading organizations excelled by accelerating clinical collaboration, strengthening supply chain resiliency, and advancing AI and digital capabilities. These strategies help maintain supply assurance during disruptions and improve day-to-day performance.

Barclays maintains McKesson at Overweight, raises price target to $1235 from $1000

https://www.tradingview.com/news/tradingview:f32ed5c5b1f26:0-barclays-maintains-mckesson-at-overweight-raises-price-target-to-1235-from-1000/
Barclays has reiterated its Overweight rating on McKesson (MCK) and increased its price target from $1000 to $1235, representing a 23.5% hike. This new target implies a 13.1% upside from the stock's November 17 closing price of $1091.67. Other analysts have recently issued price targets for McKesson ranging from $965 to $1255.

McKesson (MCK) Q2 Growth Keeps Undervalued Narrative In Focus

https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/mckesson-mck-q2-growth-keeps-undervalued-narrative-in-focus
McKesson (MCK) recently reported strong Q2 results with sales of US$110.96b and net income of US$1.22b, leading to positive stock momentum. Simply Wall St's analyst consensus indicates the stock is 4.6% undervalued, with a fair value of $1,144.29 compared to its current price of $1,091.67. While future cash flows suggest undervaluation, the P/E ratio appears high relative to industry peers, suggesting a mixed valuation picture.
Advertisement

Option Care Health Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Option Care Health, Inc. - OPCH

https://www.businesswire.com/news/home/20261117840344/en/Option-Care-Health-Investor-Alert-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Option-Care-Health-Inc.---OPCH
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Option Care Health, Inc. (NasdaqGS: OPCH) to CD&R, McKesson Corporation, where shareholders are set to receive $32.05 in cash per share. KSF aims to determine if this consideration and the sale process are adequate or if the company is undervalued. Shareholders who believe the transaction undervalues the company are encouraged to contact KSF to discuss their legal rights.

WaFd Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of WaFd, Inc. - WAFD

https://www.businesswire.com/news/home/20261117004173/en/WaFd-Investor-Alert-Kahn-Swick-Foti-LLC-Investigates-Merger-of-WaFd-Inc.---WAFD
Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger between WaFd, Inc. (NasdaqGS: WAFD) and EverBank Financial Corp, where WaFd shareholders are expected to own 40.8% of the combined company. KSF is assessing whether the merger and its preceding process are fair and adequate to WaFd shareholders. Shareholders can contact KSF to discuss their legal rights regarding the transaction.

How Baxter Boosts Medical Circularity And Net Zero Targets

https://sustainabilitymag.com/news/how-baxter-boosts-medical-circularity-and-net-zero-targets
Baxter, a leading medical technology company, is striving for both medical circularity and net zero emissions by 2050, despite the challenges of maintaining strict sterility standards for its products. Chief Sustainability Officer Renae Kerzar explains how Baxter integrates material reduction into product engineering, collaborates with healthcare systems to manage waste, and implements a global plan to decarbonize its operations, aiming for 100% clean, renewable electricity by 2040. The company also emphasizes the importance of "double materiality" to align sustainability efforts with financial and risk management goals, and partners with other healthcare organizations to advance circularity and reduce emissions across the supply chain.

McKesson Corp. stock underperforms Tuesday when compared to competitors

https://www.marketwatch.com/data-news/mckesson-corp-stock-underperforms-tuesday-when-compared-to-competitors-f725d19a-3fa4e1ca4538?mod=mw_quote_news
Shares of McKesson Corp. (MCK) fell by 1.21% on Tuesday, closing at $1,091.67, in a generally negative trading session for the stock market. This decline occurred as the S&P 500 Index and Dow Jones Industrial Average also experienced significant drops. The stock's fall ended a two-day winning streak.

UnitedHealth's outside review praised how medical policies are written—but did not examine the denials patients actually experience

https://www.medicaldaily.com/unitedhealth-review-medical-policy-coverage-denials-481331
An outside review commissioned by UnitedHealth Group found that its insurance arm uses a strong, evidence-based process to write medical policies, but the review notably did not examine how these policies are applied to individual patients, including approval or denial of care. This omission is significant for patients and doctors who frequently dispute UnitedHealthcare's denial decisions. While the review praised the company's policy development, outside data from KFF and the HHS inspector general indicate high denial rates and overturn rates on appeal for UnitedHealthcare, suggesting a disconnect between policy quality and patient experience.
Advertisement

McKesson stock at EUR 1,001.75, down 0.91% premarket

https://www.ad-hoc-news.de/boerse/news/vorboerse/mckesson-stock-at-eur-1-001-75-down-0-91-premarket/70525158
McKesson stock opened premarket trading down 0.91% at EUR 1,001.75, following a close of EUR 1,011.00 on Monday. The company recently raised its fiscal 2027 adjusted EPS outlook to USD 45.60-46.40, up from USD 44.20-45.00, after strong second-quarter results driven by higher-margin oncology and technology businesses. Strategic initiatives include the planned Medical-Surgical separation and a proposed investment in Option Care Health.

PENN Entertainment, Inc. (PENN) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/MS_0P000004A0_AnalystReport_1794842119000
This Morningstar analyst report, published on November 16, 2026, provides an overview of PENN Entertainment, Inc. The report highlights Penn's origins as a 1972 racetrack and its current operation of 42 properties across 19 states, with land-based casinos accounting for 81% of its 2025 sales. Dan Wasiolek, a Senior Equity Analyst covering gaming and lodging, authored the report.

Revenue rose to $2.05M, but Quanome Technologies (QNME) remained in the red.

https://www.stocktitan.net/sec-filings/QNME/10-q-quanome-technologies-inc-quarterly-earnings-report-d6d70771805f.html
Quanome Technologies (QNME) reported increased revenue of $2.05 million for the three months ended September 30, 2026, up from $1.34 million a year earlier, primarily driven by higher sales of infusion products and new customers. Despite the revenue growth and an improved gross profit margin, the company posted a net loss of $664,270 and raised substantial doubt about its ability to continue as a going concern, citing reliance on external financing. The company is also expanding into AI computing infrastructure and evaluating quantum-related technologies, with significant capital expenditure commitments for new equipment.

McKesson's (NYSE:MCK) Solid Earnings Are Supported By Other Strong Factors

https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/mckessons-nysemck-solid-earnings-are-supported-by-other-stro
McKesson Corporation's recent strong earnings report led to a positive stock price movement, further supported by encouraging underlying factors. The company boasts a negative accrual ratio of -0.93, indicating that its statutory earnings are significantly less than its free cash flow, which stood at US$6.9 billion compared to a reported profit of US$4.70 billion. This strong free cash flow generation and a 53% annual earnings per share growth over the last three years suggest that McKesson's true earnings potential might be even stronger than reported.

McKesson stock: JPMorgan lifts price target to $1,255

https://www.ad-hoc-news.de/boerse/news/corporate-news/mckesson-stock-jpmorgan-lifts-price-target-to-1-255/70521514
JPMorgan has reaffirmed its Overweight rating for McKesson stock and increased its price target from $1,042 to $1,255. This adjustment follows market attention on McKesson's recent earnings performance and healthcare services strategy. On Monday, November 16, McKesson stock traded at 1,008.50 euros on Lang & Schwarz.
Advertisement

Here's How Much $1000 Invested In McKesson 15 Years Ago Would Be Worth Today

https://www.benzinga.com/news/26/11/63301878/here-s-how-much-1000-invested-mckesson-15-years-ago-would-be-worth-today
McKesson (NYSE: MCK) has significantly outperformed the market over the last 15 years, achieving an average annual return of 19.38%. An initial investment of $1000 in MCK stock 15 years ago would now be worth $14,168.33. This demonstrates the substantial impact of compounded returns on investment growth over time.

Will Strong Quarterly Earnings Change McKesson (MCK) Stock Narrative

https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/will-strong-quarterly-earnings-change-mckesson-mck-stock-nar
McKesson (MCK) reported strong Q2 2026 results with US$110.96 billion in sales and US$1.22 billion in net income, delivering a basic EPS of US$10.47. These earnings reinforce the company's existing narrative of being a high-volume, low-margin healthcare distributor expanding into oncology and access platforms. While the new data supports the operational story, core catalysts and risks, such as regulatory pressures and cyber incidents, remain unchanged, with analysts forecasting continued revenue and earnings growth through 2029.

Two Medical Giants Diverge in Strategy as Investors Face a Choice Between Steady Returns and High Growth

https://nai500.com/blog/2026/11/two-medical-giants-diverge-in-strategy-as-investors-face-a-choice-between-steady-returns-and-high-growth/
Amgen (AMGN) and Vertex Pharmaceuticals (VRTX) offer investors distinct choices: Amgen provides steady returns with a lower valuation, strong cash flow, and diversified operations, appealing to those seeking stability. Vertex, while growing faster with conservative finances and a promising pipeline, comes with a higher valuation and concentrated revenue. Investors must weigh these differences based on their individual risk and return preferences.

McKesson Corp. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/mckesson-corp-stock-outperforms-competitors-on-strong-trading-day-f0481583-bf56da406122?mod=goog_fin_scmw
Shares of McKesson Corp. (MCK) rose 2.39% to $1,102.81 on Friday, outperforming the mixed market session where the Dow Jones Industrial Average gained 0.10% and the S&P 500 Index fell 0.40%. This increase ended a two-day losing streak for the stock.

How reimbursement rules can break your deal: Lessons from Capricor Therapeutics, Inc. v. NS Pharma, Inc.

https://www.winstontaylor.com/insights/how-reimbursement-rules-can-break-your-deal-lessons-from-capricor-therapeutics-inc-v-ns-pharma-inc
This article analyzes the legal dispute between Capricor Therapeutics, Inc. and NS Pharma, Inc., highlighting how the deal's structure failed to account for Medicare Part B reimbursement mechanics. The core issue is that NS Pharma's commercialization costs and milestone obligations required a markup that Medicare's ASP+6% reimbursement model, based on Capricor's transfer price, could not accommodate, leading to financial disincentives for healthcare providers. The case underscores the critical need for life sciences companies to thoroughly model reimbursement economics for provider-administered therapies before finalizing commercialization agreements.
Advertisement

McKesson stock lifts fiscal 2027 outlook after strong Q2

https://www.ad-hoc-news.de/boerse/news/corporate-news/mckesson-stock-lifts-fiscal-2027-outlook-after-strong-q2/70504741
McKesson reported strong fiscal second-quarter revenue of $111.0 billion, an 8% increase year over year, with adjusted diluted earnings per share rising 18% to $11.68. The company also expanded its specialty-care strategy and increased its fiscal 2027 adjusted diluted earnings guidance to $45.60-$46.40 per share, citing operational strength and disciplined execution.

Healthcare providers & services stocks Q3 results: Benchmarking McKesson

https://www.tradingview.com/news/stockstory:7b895c628094b:0-healthcare-providers-services-stocks-q3-results-benchmarking-mckesson/
This article benchmarks McKesson (MCK) and its peers' Q3 performance within the healthcare providers & services sector. McKesson reported solid revenue and EPS beats, while LifeStance Health Group (LFST) had the best Q3 with strong revenue growth and raised guidance. Brookdale (BKD) experienced the weakest Q3 with declining revenues and a significant stock drop.

Healthcare providers & services stocks Q3 results: Benchmarking McKesson

https://stockstory.org/us/stocks/nyse/mck/news/earnings/healthcare-providers-and-services-stocks-q3-results-benchmarking-mckesson
This article analyzes the Q3 earnings of McKesson and its peers in the healthcare providers and services sector. It highlights McKesson's solid performance with revenues exceeding expectations, while LifeStance Health Group posted the strongest results, and Brookdale showed the weakest revenue growth. The sector as a whole reported solid Q3 results, with revenues beating consensus estimates.

We Like Cardinal Health's (NYSE:CAH) Earnings For More Than Just Statutory Profit

https://simplywall.st/stocks/us/healthcare/nyse-cah/cardinal-health/news/we-like-cardinal-healths-nysecah-earnings-for-more-than-just
Cardinal Health (NYSE:CAH) recently reported strong earnings, which was well-received by the market. Analysis of the accrual ratio revealed a negative value of -2.58 for the year to September 2026, indicating that the company's free cash flow significantly exceeded its reported profit. Additionally, unusual items reduced profit by US$840m, suggesting that without these non-recurring charges, future profits could be higher, leading to an optimistic outlook on Cardinal Health's earnings potential.

Hospitals write off $132B as AI fails to move the needle with finances

https://www.techtarget.com/revcyclemanagement/news/366654662/Hospitals-write-off-132B-as-AI-fails-to-move-the-needle-with-finances
Hospitals experienced an estimated $132 billion in write-offs last year due to bad debt and final claim denials, an 18% increase from 2024, despite growing investments in revenue cycle technology, including AI tools. The analysis suggests that while AI streamlines processes, it may not be providing the in-depth data analysis needed to optimize financial performance or address structural issues like prior authorizations. This puts hospitals in an "AI arms race" with payers, requiring strategic technology investments to remain competitive and improve key financial indicators.
Advertisement

McKesson stock gains as fiscal 2027 earnings outlook rises

https://www.ad-hoc-news.de/boerse/news/corporate-news/mckesson-stock-gains-as-fiscal-2027-earnings-outlook-rises/70493018
McKesson's stock is up following strong fiscal second-quarter results and a raised fiscal 2027 earnings outlook. The company reported an 8% increase in revenue and an 18% rise in adjusted diluted EPS year over year. McKesson expects continued growth across its operating segments and higher profit momentum, driven by gains in North American Pharmaceutical, Oncology & Multispecialty, and Prescription Technology Solutions.

CVS announces breakup, but its Ohio skeptics say it’s incomplete

https://www.newsfromthestates.com/article/cvs-announces-breakup-its-ohio-skeptics-say-its-incomplete
CVS recently announced a corporate split into CVS Health and CVS Pharmacy, aiming for more focus and better customer experience, with completion expected in 2028. However, Ohio-based drug pricing expert Antonio Ciaccia views this as CVS divesting less profitable assets while retaining its most lucrative operations, including specialty drugs and its pharmacy benefit manager. Critics, including the American Economic Liberties Project, argue the split fails to address core conflicts of interest present when the same company owns both insurers and providers, which they believe drives up healthcare costs.

CVS announces breakup, but its Ohio skeptics say it’s incomplete

https://ohiocapitaljournal.com/2026/11/11/cvs-announces-breakup-but-its-ohio-skeptics-say-its-incomplete/
CVS recently announced a corporate split into CVS Health and CVS Pharmacy, aiming for increased focus and better customer experience, with completion expected by 2028. However, critics like Antonio Ciaccia argue that the breakup primarily separates less profitable retail operations from lucrative pharmacy benefit management (PBM) and insurance sectors, including high-profit specialty drugs, without addressing core conflicts of interest in healthcare costs. The American Economic Liberties Project views it as an attempt to preempt more substantial reforms, though some believe it eliminates conflicts related to PBM reimbursements to independent pharmacies.

McKesson (MCK) Posts Strong Q2 Growth, Is The Upside Already Priced In?

https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/mckesson-mck-posts-strong-q2-growth-is-the-upside-already-pr
McKesson (MCK) reported strong Q2 earnings with sales of US$110.957 billion and net income of US$1.218 billion, following significant share price gains over the past year. While analysts suggest the stock is 6% overvalued at $1,082.59 compared to a fair value of $1,026.07, the Simply Wall St DCF model indicates a much higher potential value of $1,980.95. Investors are weighing the company's strong oncology and biopharma strategy against potential risks like regulatory pressure and cyber incidents.

McKesson Corp. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/mckesson-corp-stock-outperforms-competitors-on-strong-trading-day-69414439-70a64ff0a8d9?mod=goog_fin_scmw
Shares of McKesson Corp. (MCK) rose 2.19% to $1,082.59 on Tuesday, contrasting with a general market decline where the S&P 500 Index and Dow Jones Industrial Average both fell. This increase ended a two-day losing streak for McKesson's stock.
Advertisement

Henry Schein (NASDAQ:HSIC) Q3 2026: EPS Beat, Guidance Raised

https://kalkinemedia.com/us/stocks/healthcare/henry-schein-nasdaqhsic-q3-2026-eps-beat-guidance-raised
Henry Schein, Inc. (NASDAQ:HSIC) reported strong third-quarter 2026 results, with adjusted earnings per share exceeding analyst expectations and revenue aligning with forecasts. The company raised its full-year non-GAAP earnings guidance, attributing the profit growth to efficiency programs and a shift towards higher-margin specialty products and technology solutions. Despite modest top-line growth, cost management and a richer product mix have significantly boosted profitability.

McKesson Credits AI, Automation Investments with Improving Distribution Performance

https://distributionstrategy.com/2026/11/mckesson-credits-ai-automation-investments-with-improving-distribution-performance/
McKesson's CEO Brian Tyler attributes the company's improved distribution performance to years of strategic investments in technology, including AI, robotic process automation, and physical distribution. While McKesson has not quantified AI's direct financial contribution, it views large language models as integral to its broader strategy for efficiency, customer service, and profitability, rather than a standalone initiative. The company reported strong fiscal second-quarter revenue and net income, with growth in its pharmaceutical distribution and specialty health care businesses, supported by these ongoing technology and automation investments.

McKesson stock raises fiscal 2027 adjusted EPS outlook

https://www.ad-hoc-news.de/boerse/news/corporate-news/mckesson-stock-raises-fiscal-2027-adjusted-eps-outlook/70486104
McKesson has strengthened its profit outlook for fiscal 2027 after reporting an 8% increase in second-quarter revenue. The company raised its adjusted EPS guidance for fiscal 2027 to a range of $45.60 to $46.40, reflecting strong operational growth across key segments. McKesson also completed the acquisition of Precision Medicine Group and plans a strategic investment in Option Care Health.

SAP Expands Collaboration with AstraZeneca to Adopt RISE with SAP and Business AI

https://news.sap.com/2026/11/sap-expands-collaboration-astrazeneca-rise-with-sap-business-ai/
SAP SE announced that AstraZeneca is migrating to SAP Cloud ERP Private through the RISE with SAP journey, expanding their 20-year relationship. This full-estate migration aims to simplify AstraZeneca's technology landscape, enabling faster operations, better decision-making, and leveraging AI capabilities. The collaboration will also support AstraZeneca in building a clean data core and embedding sustainability into its core business processes.

Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment

https://www.tradingview.com/news/prnewswire:91a696f58c733:0-raised-outlooks-and-a-cancer-approval-arrive-in-the-middle-of-medicare-open-enrollment/
Several healthcare companies, including Johnson & Johnson, Vertex Pharmaceuticals, Humana, Edwards Lifesciences, and McKesson, reported positive developments amidst Medicare Open Enrollment. Four of the five companies raised their full-year guidance, and Johnson & Johnson received accelerated FDA approval for a new cancer therapy. These updates highlight significant activity in the pharmaceutical, biotechnology, health insurance, medical devices, and drug distribution sectors.
Advertisement

DataMEDS Completes First Compounded Peptide Sale

https://grafa.com/en/news/united-states/datameds-ai-corexa-pharmacy-first-compounded-peptide-sale
DataMEDS AI announced that its Corexa Pharmacy subsidiary has completed its first commercial sale of a compounded peptide, operating under the HHS Enforcement Discretion Policy. The sale involved one of six peptides identified by the FDA's Pharmacy Compounding Advisory Committee, though these compounded drugs are not FDA-approved. The company is developing its pricing model and intends to market these offerings to prescribing physicians.

McKesson stock lifts fiscal 2027 EPS outlook after Q2 growth

https://www.ad-hoc-news.de/boerse/news/corporate-news/mckesson-stock-lifts-fiscal-2027-eps-outlook-after-q2-growth/70481137
McKesson reported stronger fiscal second-quarter results on November 4, 2026, with revenue up 8 percent and adjusted diluted EPS rising 18 percent year over year. The company raised its fiscal 2027 adjusted diluted EPS guidance to $45.60-$46.40, implying 17-19 percent growth, citing broad segment growth and disciplined execution. McKesson also completed its Precision Medicine Group acquisition and extended its distribution partnership with CVS Health.

CorMedix Therapeutics to Acquire Substantially All Assets

https://www.globenewswire.com/news-release/2026/11/09/3398281/0/en/cormedix-therapeutics-to-acquire-substantially-all-assets-of-heron-therapeutics-expanding-its-portfolio-of-products-used-in-institutional-settings-of-care.html
CorMedix Therapeutics is set to acquire substantially all assets of Heron Therapeutics for $145 million in cash, 14,583,333 shares of CorMedix common stock, and up to $55 million in earn-out payments and royalties. This acquisition adds four commercial-stage products to CorMedix's portfolio, expanding its presence in institutional settings of care and is expected to be immediately accretive to CorMedix's earnings and free cash flow. The transaction is anticipated to close in the first quarter of 2027, subject to regulatory clearance and Heron stockholder approval.

Weekly Recap: Albumin revenue falls and Canadian collections restart

https://www.tradingview.com/news/tradingview:bfd545903698d:0-weekly-recap-albumin-revenue-falls-and-canadian-collections-restart/
Grifols (GRF) reported a decline in albumin revenue for the third quarter and first nine months of 2026, citing a slow recovery in China. Concurrently, the company has begun a phased restart of plasma collection at its 17 Canadian centers after a temporary pause. Grifols also achieved €208 million in third-quarter free cash flow before M&A and does not anticipate an update on its potential U.S. Biopharma IPO review until 2027.

Cardinal Health (CAH) Lifts Guidance As Investors Ask If The Story Is Fully Valued

https://simplywall.st/stocks/us/healthcare/nyse-cah/cardinal-health/news/cardinal-health-cah-lifts-guidance-as-investors-ask-if-the-s
Cardinal Health (CAH) reported a stronger-than-expected first quarter with increased revenue and earnings, leading to raised fiscal 2027 profit guidance. The company's stock has seen significant gains, though its current valuation is considered fair based on long-term earnings forecasts. However, its high P/E ratio compared to peers suggests investors are already paying a premium for the growth story, prompting questions about future upside potential.
Advertisement

McKesson Q2 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:2d8b64548094b:0-mckesson-q2-earnings-call-highlights/
McKesson (MCK) raised its fiscal 2027 adjusted earnings outlook after reporting strong second-quarter revenue and profit, driven by prescription volumes, specialty distribution, and demand for medication access services. The company now expects adjusted earnings of $45.60 to $46.40 per diluted share and reported an 8% increase in Q2 revenue to $111 billion. McKesson also announced the acquisition of Precision Medicine Group for $2.25 billion and an investment of $1.4 billion for a minority interest in Option Care Health.

5 insightful analyst questions from McKesson’s Q3 CY2026 earnings call

https://stockstory.org/us/stocks/nyse/mck/news/earnings-call/5-insightful-analyst-questions-from-mckessons-q3-cy2026-earnings-call
McKesson reported strong Q3 CY2026 results driven by pharmaceutical distribution and specialty services, with revenue reaching $111 billion and adjusted EPS of $11.68, both beating analyst estimates. The company raised its full-year adjusted EPS guidance. Key analyst questions focused on the integration and impact of recent acquisitions like Precision Medicine Group and Option Care Health, the sustainability of growth in North American Pharmaceutical, and potential effects of 340B policy changes.

Form 4 McKesson: Francisco Fraga (EVP, CIO and CTO) For: 5 November

https://uk.investing.com/news/stock-market-news/form-4-mckesson-francisco-fraga-evp-cio-and-cto-for-5-november-93CH-4965646
This article reports on a Form 4 filing for McKesson, detailing insider transactions by Francisco Fraga, Executive Vice President, Chief Information Officer, and Chief Technology Officer. The filing is specific to November 5th. The article is brief and primarily serves as a notification of this corporate disclosure.

Form 4 MCKESSON CORP For: Nov 05 Filed by: Fraga Francisco

https://www.streetinsider.com/SEC+Filings/Form+4+MCKESSON+CORP+For%3A+Nov+05+Filed+by%3A+Fraga+Francisco/27306472.html
This SEC Form 4 filing reports a transaction by Francisco Fraga, EVP, CIO, and CTO of MCKESSON CORP (MCK), on November 5, 2026. Fraga disposed of 650 shares of common stock at a price of $1,102.96 per share, leaving a beneficial ownership of 4,414.496 shares. This sale was conducted under a Rule 10b5-1(c) plan adopted on March 10, 2026.

Cencora fiscal Q4 revenue rises 5.5% to $88.4 billion, adjusted EPS up 21% to $4.66; fiscal 2027 guide $19.40-$19.75

https://mlq.ai/news/cencora-fiscal-q4-revenue-rises-55-to-884-billion-adjusted-eps-up-21-to-466-fiscal-2027-guide-1940-1975/
Cencora reported a 5.5% increase in fiscal Q4 2026 revenue to $88.4 billion, with adjusted diluted EPS up 21.4% to $4.66. The company also provided fiscal 2027 guidance, projecting adjusted EPS of $19.40-$19.75, along with revenue growth of 3% to 5% and adjusted operating income growth of 4% to 6%. Additionally, Cencora announced a 10% increase in its quarterly dividend to $0.66 per share.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement